Efavirenz (Stocrin) 200 mg and 600 mg tablets: Supply issue
The supplier of efavirenz (Stocrin) 200 mg and 600 mg has discontinued its efavirenz tablets worldwide.
6 March 2025
We have consulted on this discontinuation. The consultation has closed and we are reviewing the feedback we received.
Affected products
The supplier discontinued its efavirenz tablets. Stocrin brand stopped being funded from 1 December 2024.
Chemical: Efavirenz
Presentation: Tab 600 mg
- Brand: Stocrin
- Pharmacode: 2060094
- Subsidy: $63.38
- Measure / Qty: per 30
Presentation: Tab 200 mg
- Brand: Stocrin
- Pharmacode: 2292483
- Subsidy $190.15
- Measure / Qty: per 90
Temporary alternative funded
We listed an alternative brand of efavirenz 600 mg tablets from 1 April 2024 so that people could access their treatment. This will remain funded while stock is available.
- Brand: Efavirenz Milpharm
- Pharmacode: 2676915
- Subsidy: $65.38
- Measure / Qty: 30
- Wastage applies - Section 29
This product is not Medsafe approved but is approved in the UK.
Datasheet for Efavirenz Milpharm on Medicines.org.uk(external link)
What does this mean for me?
If you take efavirenz, you will need to talk to the person who prescribed it. There are other funded treatments available.
Prescribers
Please reach out to any one you prescribe efavirenz for. They will need to move to a new funded treatment.
NZF Formulary information on HIV infection(external link)
Pharmacists
If you dispense efavirenz, please encourage your patient to talk to their prescriber to find a suitable alternative treatment.
When will this happen?
Following the consultation, we will likely stop funding efavirenz later in 2025
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)